Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295088478> ?p ?o ?g. }
- W4295088478 endingPage "685" @default.
- W4295088478 startingPage "679" @default.
- W4295088478 abstract "We aimed to evaluate the seroconversion rates after two doses of inactive COVID-19 vaccine (CoronaVac) and the benefit of a third dose mRNA vaccine booster in patients with cancer receiving active treatment. Patients with solid tumors receiving active treatment (n = 101) and patients with no-cancer (n = 48) as the control group were included in the study. All the patients and controls had received two doses of CoronaVac and a third booster dose of the mRNA vaccine (Bnt162b2). Anti-SARS-CoV-2 Spike Receptor Binding Domain IgG antibody levels after the second and third dose were measured with quantitative ELISA. The median age of the patients was 66 (IQR 60-71). 79% of the patients were receiving chemotherapy, and 21% were receiving immunotherapy at the time of vaccination. Antibody levels measured after two doses of CoronaVac were significantly lower in patients with cancer than in the control group (median 0 μg/ml [IQR 0-1.17 μg/ml] vs median 0.91 μg/ml [IQR 0-2.24 μg/ml], respectively, P = .002). Seropositivity rates were 46.5% in patients with cancer and 72.9% in the control group (P = .002). Antibody measurement was performed in 26 patients after the third dose. Seroconversion rate increased from 46.5% to 88.5% (P < .001), and the antibody titers significantly increased with the third-dose booster (median 0 μg/ml [IQR 0-1.17 μg/ml] after two doses vs 12.6 μg/ml [IQR 1.8-69.1 μg/ml] after third booster dose, P < .001). Immunogenicity of CoronaVac is low in patients with cancer receiving active treatment, and administering a third dose of an mRNA vaccine is effective in terms of improving seroconversion rates." @default.
- W4295088478 created "2022-09-10" @default.
- W4295088478 creator A5011306956 @default.
- W4295088478 creator A5026279555 @default.
- W4295088478 creator A5030454474 @default.
- W4295088478 creator A5033323622 @default.
- W4295088478 creator A5036552296 @default.
- W4295088478 creator A5047643020 @default.
- W4295088478 creator A5047814313 @default.
- W4295088478 creator A5050063396 @default.
- W4295088478 creator A5052748672 @default.
- W4295088478 creator A5053670045 @default.
- W4295088478 creator A5058504269 @default.
- W4295088478 creator A5059549179 @default.
- W4295088478 creator A5064292428 @default.
- W4295088478 creator A5072870318 @default.
- W4295088478 creator A5090594476 @default.
- W4295088478 date "2022-09-23" @default.
- W4295088478 modified "2023-10-12" @default.
- W4295088478 title "Immunogenicity of two doses of inactive <scp>COVID</scp>‐19 vaccine and third booster dose <scp>mRNA</scp> vaccine in patients with cancer receiving active systemic therapy" @default.
- W4295088478 cites W1969423723 @default.
- W4295088478 cites W2920466137 @default.
- W4295088478 cites W3034965161 @default.
- W4295088478 cites W3036757697 @default.
- W4295088478 cites W3047919115 @default.
- W4295088478 cites W3080162924 @default.
- W4295088478 cites W3091376205 @default.
- W4295088478 cites W3098511379 @default.
- W4295088478 cites W3110244214 @default.
- W4295088478 cites W3112725274 @default.
- W4295088478 cites W3156866359 @default.
- W4295088478 cites W3164768289 @default.
- W4295088478 cites W3174178131 @default.
- W4295088478 cites W3178010802 @default.
- W4295088478 cites W3189962712 @default.
- W4295088478 cites W3194089520 @default.
- W4295088478 cites W3196773066 @default.
- W4295088478 cites W3201177512 @default.
- W4295088478 cites W3206895259 @default.
- W4295088478 cites W3210126657 @default.
- W4295088478 cites W3214546414 @default.
- W4295088478 cites W4200298142 @default.
- W4295088478 cites W4206987853 @default.
- W4295088478 cites W4210262630 @default.
- W4295088478 cites W4210450230 @default.
- W4295088478 cites W4225725936 @default.
- W4295088478 cites W4283465445 @default.
- W4295088478 doi "https://doi.org/10.1002/ijc.34280" @default.
- W4295088478 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36082448" @default.
- W4295088478 hasPublicationYear "2022" @default.
- W4295088478 type Work @default.
- W4295088478 citedByCount "0" @default.
- W4295088478 crossrefType "journal-article" @default.
- W4295088478 hasAuthorship W4295088478A5011306956 @default.
- W4295088478 hasAuthorship W4295088478A5026279555 @default.
- W4295088478 hasAuthorship W4295088478A5030454474 @default.
- W4295088478 hasAuthorship W4295088478A5033323622 @default.
- W4295088478 hasAuthorship W4295088478A5036552296 @default.
- W4295088478 hasAuthorship W4295088478A5047643020 @default.
- W4295088478 hasAuthorship W4295088478A5047814313 @default.
- W4295088478 hasAuthorship W4295088478A5050063396 @default.
- W4295088478 hasAuthorship W4295088478A5052748672 @default.
- W4295088478 hasAuthorship W4295088478A5053670045 @default.
- W4295088478 hasAuthorship W4295088478A5058504269 @default.
- W4295088478 hasAuthorship W4295088478A5059549179 @default.
- W4295088478 hasAuthorship W4295088478A5064292428 @default.
- W4295088478 hasAuthorship W4295088478A5072870318 @default.
- W4295088478 hasAuthorship W4295088478A5090594476 @default.
- W4295088478 hasBestOaLocation W42950884782 @default.
- W4295088478 hasConcept C121332964 @default.
- W4295088478 hasConcept C12590561 @default.
- W4295088478 hasConcept C126322002 @default.
- W4295088478 hasConcept C1276947 @default.
- W4295088478 hasConcept C159654299 @default.
- W4295088478 hasConcept C203014093 @default.
- W4295088478 hasConcept C203165030 @default.
- W4295088478 hasConcept C22070199 @default.
- W4295088478 hasConcept C2777451964 @default.
- W4295088478 hasConcept C2780868878 @default.
- W4295088478 hasConcept C32611913 @default.
- W4295088478 hasConcept C71924100 @default.
- W4295088478 hasConcept C90924648 @default.
- W4295088478 hasConceptScore W4295088478C121332964 @default.
- W4295088478 hasConceptScore W4295088478C12590561 @default.
- W4295088478 hasConceptScore W4295088478C126322002 @default.
- W4295088478 hasConceptScore W4295088478C1276947 @default.
- W4295088478 hasConceptScore W4295088478C159654299 @default.
- W4295088478 hasConceptScore W4295088478C203014093 @default.
- W4295088478 hasConceptScore W4295088478C203165030 @default.
- W4295088478 hasConceptScore W4295088478C22070199 @default.
- W4295088478 hasConceptScore W4295088478C2777451964 @default.
- W4295088478 hasConceptScore W4295088478C2780868878 @default.
- W4295088478 hasConceptScore W4295088478C32611913 @default.
- W4295088478 hasConceptScore W4295088478C71924100 @default.
- W4295088478 hasConceptScore W4295088478C90924648 @default.
- W4295088478 hasIssue "4" @default.
- W4295088478 hasLocation W42950884781 @default.
- W4295088478 hasLocation W42950884782 @default.